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ABSTRACT
Ribonucleases play essential roles in all aspects
of RNA metabolism, including the coordination of
post-transcriptional gene regulation that allows
organisms to respond to internal changes and
environmental stimuli. However, as inherently
destructive enzymes, their activity must be
carefully controlled. Recent research exemplifies
the repertoire of regulatory strategies employed by
ribonucleases. The activity of the phosphorolytic
exoribonuclease, polynucleotide phosphorylase
(PNPase), has previously been shown to be
modulated by the Krebs cycle metabolite citrate
in Escherichia coli. Here, we provide evidence
for the existence of citrate-mediated inhibition
of ribonucleases in all three domains of life.
In silico molecular docking studies predict that
citrate will bind not only to bacterial PNPases
from E. coli and Streptomyces antibioticus, but
also PNPase from human mitochondria and the
structurally and functionally related archaeal
exosome complex from Sulfolobus solfataricus.
Critically, we show experimentally that citrate also
inhibits the exoribonuclease activity of bacterial,
eukaryotic and archaeal PNPase homologues in
vitro. Furthermore, bioinformatics data, showing
key citrate-binding motifs conserved across a broad
range of PNPase homologues, suggests that this
regulatory mechanism may be widespread. Overall,
our data highlight a communicative link between
ribonuclease activity and central metabolism that
may have been conserved through the course of
evolution.
INTRODUCTION
Ribonucleases (RNases) are ubiquitous enzymes that play
central roles in RNA metabolism. They are required for
the control of gene expression, primarily through the
degradation of mRNAs, the processing and degradation
of regulatory RNAs and for the maturation and quality
control of stable RNAs (1). However, they also have the
potential to be incredibly destructive and, consequently,
their activity is carefully regulated (2).
Polynucleotide phosphorylase (PNPase) is a processive
3′-5′ phosphorolytic exoribonuclease that can also catalyse
template-independent 5′-3′ polymerisation of RNA (3,4). It
is widely distributed in bacteria and eukaryotic organelles,
but absent from archaea and single-celled eukaryotes such
as yeasts (5). PNPases typically contain five domains: two
phosphorolysis or RNase PH-like domains (PH-1 and PH-
2) separated by an alpha helical domain (H), followed
by two RNA-binding domains (KH and S1) (Figure 1A;
5,6). Eukaryotic PNPases also contain anN-terminal signal
peptide to target them to the mitochondria or chloroplast
(7,8). Structural studies of PNPase from Escherichia coli
(EcPNPase; Figure 1B; 9,10), Streptomyces antibioticus
(SanPNPase; 6), Caulobacter crescentus (11), Coxiella
burnetii (12) and Homo sapiens (hPNPase; Figure 1B; 13)
have revealed a ring-shaped homotrimeric complex, with a
core hexamer of PH domains that form a central channel
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Figure 1. Structural conservation of prokaryotic PNPase, eukaryotic PNPase and the archaeal exosome. (A) Schematic representation of the domain
organisation of PNPase and the archaeal exosome. The approximate locations of the four motifs (RNA-binding region I (RBRI), RNA-Binding Region
II (RBRII), phosphate binding region (PBR) and metal binding region (MBR)) that make up the catalytic centre are indicated with arrows. (B) Crystal
structures of the PH-hexamer core for E. coli PNPase (blue; 3GCM; 9),H. sapiens PNPase (red; 3U1K; 13) and S. solfataricus Exosome (green; 4BA1; 23).
(C) Sequence alignment of the four active site motifs (14) in PNPase and the archaeal exosome. Accession numbers are given in Supplementary Table S6.
Residues observed to be involved in citrate-binding in the EcPNPase (9,47) and hPNPase (13) crystal structures are indicated above the sequences by dark
orange and light orange triangles, respectively. Residues interacting with the catalytic Mg2+ ion are indicated below the sequences by magenta spheres.
that is able to accommodate single-stranded RNA. The
RNA-binding domains are positioned on one side of the PH
ring where they can guide RNA into the channel towards
the active site (6,10–13). Both structural and mutagenesis
approaches have been used to define the architecture of
the active site, which is composed of four sub-sites: two
RNA-binding regions (RBRI and RBRII), an inorganic
phosphate-binding region (PBR) and a divalent metal ion-
binding region (MBR) (Figure 1A and C; 14). The catalytic
centre is located entirely within the PH-2 domain and
comprises the MBR and PBR. Two conserved aspartates,
D486 and D492 in EcPNPase, co-ordinate a Mg2+ ion
and an S[S/T]S motif, S437, S438 and S439 in EcPNPase,
is predicted to bind the inorganic phosphate (Figure
1C; 9,14,15). RBRI and RBRII, formed by conserved
motifs in the PH-1 domain and PH-2 domain, respectively,
contribute conserved arginines, EcPNPaseR93, R97, R100,
R398 andR399 and a histidine, EcPNPaseH403 (Figure 1A
and C; 9,14–16).
Although PNPase is not present in archaea (5) there
is a structurally and functionally equivalent complex, the
exosome (17). The archaeal exosome complex contains
five different proteins: Rrp42 (equivalent to PH-1), Rrp41
(equivalent to PH-2) and three RNA-binding proteins
namedRrp4 (contains S1 andKHdomains), Csl4 (contains
S1 and Zn-finger domains) and DnaG (binds polyA)
(Figure 1A; 18). Structural studies of exosomes from
Sulfolobus solfataricus (SsoExosome; Figure 1B; 19–23),
Archaeoglobus fulgidus (24,25), Pyrococcus abyssi (26)
and Methanothermobacter thermautotrophicus (27) have
revealed a similar architecture to PNPase. A trimer of
Rrp41/Rrp42 dimers form the ring-shaped PH-domain
hexamer (19–27) and three RNA-binding proteins, Rrp4
and/or Csl4-DnaG, assemble on one face of the ring
where they channel RNA towards the active site (21–25).
The RNA-binding motifs (RBRI and II) and the metal-
binding motif (MBR) are conserved between PNPase and
the archaeal exosome (Figure 1C), however, the phosphate-
binding S[S/T]S motif in PNPase has been replaced by
a G[S/T]R motif in the exosome (Figure 1C; 23,27).
Exosome complexes are also found in eukaryotes, but,
unlike their archaeal counterparts, their PH-core does not
possess phosphorolytic activity (28,29). Instead, they rely
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upon accessory proteins with hydrolytic RNase activity to
degrade RNA (29,30).
In terms of physiological function, the most studied
PNPase is that from E. coli. In this bacterium, PNPase
is required for growth at low temperatures (31) and
its activity has been implicated in all aspects of RNA
metabolism: mRNA turnover (32,33), degradation of small
regulatory RNAs (sRNAs; 34,35) and the quality control
of stable RNAs (36,37). Not surprisingly, given these
diverse roles, EcPNPase activity is tightly controlled at both
post-transcriptional and post-translational levels. Post-
transcriptionally, the stability of the pnp mRNA and,
therefore, expression of pnp is autoregulated by PNPase in
amechanism involving the endoriboculeases RNase III and
RNase E (38,39). EcPNPase can function independently
but it is also a component of severalmultiprotein complexes.
It is found in the canonical degradosome along with RNase
E, the RNA helicase RhlB and the glycolytic enzyme
enolase (40,41), it can form an 32 complex with RhlB
(42) and it associates with poly(A) polymerase and the
RNA chaperone Hfq (43). These associations with another
ribonuclease, a helicase and a polyadenylation complex
are likely to assist EcPNPase in its degradative capability.
However, localisation to the cytoplasmic membrane as part
of the degradosome (40,41,44) would serve to restrict its
activity. More recent studies have suggested that there is
also a communicative link between the cellular metabolic
state and EcPNPase activity. ATP (45) and cyclic di-
GMP (46) have been shown to modulate EcPNPase
activity in vitro and our laboratory has demonstrated that
the Krebs cycle intermediate, citrate, regulates EcPNPase
exoribonuclease activity both in vitro and in vivo at
physiological concentrations of citrate (47). Furthermore,
we have previously shown that the status of the cellular
metabolome is dependent upon EcPNPase activity (47).
In the current study, we use a combination of
bioinformatics and in silico molecular docking approaches
to show that citrate is likely to bind to PNPase and related
exoribonucleolytic proteins from diverse bacterial species,
eukaryotic organelles and archaea. Furthermore, we
demonstrate experimentally that in addition to inhibiting
E. coli PNPase, citrate also inhibits the exoribonuclease
activity of PNPases from cyanobacteria and human
mitochondria, and the archaeal exosome in vitro. It is
therefore possible that the citrate-mediated regulatory
mechanism previously identified in EcPNPase (47) may be
conserved across all three domains of life.
MATERIALS AND METHODS
Bioinformatics
Protein sequences were extracted from the NCBI
RefSeq database (Genbank) using polynucleotide
phosphorylase, for prokaryotic and eukaryotic sequences
and Rrp41/Rrp42, for archaeal sequences, as search terms.
Multiple sequence alignments were built using MAFFT
v.7 (48) using the G-INS-i iterative refinement strategy
and default parameters: BLOSUM62 and a gap penalty
of 1.53. In order to generate the sequence logos, the
alignments were manually curated to remove duplicate and
partial entries. Close homologues were omitted from the
alignments using Jalview (49) to filter out redundancy at
95% sequence identity. The remaining aligned sequences
were trimmed to the ‘PH-core’ boundaries using the known
sequence/structures as a guide (EcPNPase residues 1–549,
hPNPase 1–601, SsoExosome 1–532). The consensus
sequences for the RBRI, RBRII, PBR and MBR motifs
(14) were identified using this final set of sequences (3509
prokaryote sequences, 252 eukaryote sequences and
69 archaeal sequences; accession numbers are given in
Supplementary Tables S1–S4) and visualised as sequence
logos with the probability score on the Y-axis using
Weblogo3 (50).
In silico molecular docking
Structures for EcPNPase (3GCM, chain A; 9), hPNPase
(3U1K, chain A; 13), SanPNPase (1E3P, sole chain; 6)
and SsoExosome (4BA1, chain A; 23) were opened in the
program MOE (Molecular Operating Environment,
2013.08; Chemical Computing Group Inc., 1010
Sherbrooke St. West, Suite #910, Montreal, QC, Canada,
H3A 2R7). The chains that were selected for docking
studies were chosen based on the quality of the structure
at the enzyme’s active site, i.e. the expected citrate-binding
site. The required catalytic Mg2+ ion was placed in the
hPNPase, SanPNPase and SsoExosome structures based
on its position in EcPNPase. The structures were then
submitted to a preparation step using the LigX interface
which included structure preparation, protonation and
energy minimisation. Energy minimisation was carried
out using the conjugate gradient method with a cutoff
distance of 6 A˚, a convergence criterion of 0.01 kcal/mol
and using the Amber12:EHT force field that is specifically
parameterised for both proteins and small molecules
(51,52). Putative ligand-binding sites were identified
using the MOE Alpha Site Finder panel, which generates
hydrophobic and hydrophilic -spheres to represent
locations of tight atom packing. The appropriate ligand-
binding site was then selected using the current knowledge
of the expected citrate-binding sites for each protein and
defined by the placement of dummy atoms. The structure
of the citrate ion was obtained from the ZINC database
(53; ZINC ID: 00895081) and saved in a biologically
relevant conformation. The Docking module of MOE
was used to dock the citrate ion (the ligand) into each of
the fixed protein structures (the receptors) using ‘Triangle
Matcher’ placement methodology and 300 placement
poses. The lowest-energy 30 unique receptor-ligand
complexes were identified and scored according to the
London dG scoring function (Molecular Operating
Environment), which estimates the binding free energy
of the ligand. The receptor-ligand complexes were then
submitted to a forcefield refinement step with no second
rescoring, retaining 30 unique ligand-receptor complexes.
The docking scores (S values) for these 30 unique receptor
ligand complexes were calculated using the Generalized
Born solvation model (GB/VI; 54). This calculates the
non-bonded interaction energy (van der Waals, Coulomb
and GB implicit solvent interaction energies) between
the receptor and the ligand complex whilst excluding the
self-energies of the individual receptor and ligand atoms.
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The lowest-energy pose with a single citrate molecule
docked was selected and used as the starting structure to
dock a second citrate molecule. Protein ligand interaction
fingerprints (PLIFs) were generated in the MOE PLIF
panel for the ten lowest-energy poses, with both one
and two molecules of citrate docked, for proteins from
each of the four organisms. The frequency with which an
interaction was observed between citrate and a particular
amino acid in the docking experiments was calculated
from the PLIFs for both one and two molecules of citrate
docked and presented as a heat map generated in Plotly
(Plotly Technologies Inc., 2015).
Protein expression and purification
E. coli BL21(DE3)pLysS was transformed with the
EcPNPase expression vector, pET-Duet1 EcPNPase,
obtained from Prof. B. Luisi (University of Cambridge,
UK). EcPNPase expression was induced at an OD600 of
0.6 with 0.5 mM isopropyl -D-1-thiogalactopyranoside
(IPTG). Induced cells were grown at 20◦C for 20 h.
EcPNPase was purified as described previously (9).
The coding sequence for hPNPase (GenBank:
BC053660.1) was codon-optimised using GeneOptimizer
(GeneArt AF, Life Technologies). The resulting gene was
synthesised and ligated between the NheI and SalI sites of
pET28b (Novagen) to generate the pET-28b H6-hPNPase
expression vector for expression of hPNPase with an
N-terminal hexahistidine tag. E. coli BL21(DE3)pLysS
was transformed with pET-28b H6-hPNPase and hPNPase
expression was induced at an OD600 of 0.6 with 0.1 mM
IPTG. Induced cells were grown at 25◦C for 3 h. hPNPase
was purified as described previously (13).
The polycistronic gene encoding the Rrp4 (GenBank:
1454999), Rrp41 (GenBank: 1454998), Rrp42 (GenBank:
1454997) proteins of the SsoExosome was codon-optimised
using GeneOptimizer, synthesised and ligated between
the NdeI and XbaI sites of pETMCN-EAVNH, obtained
from Dr C. Romier (University of Strasbourg, France). E.
coli BL21(DE3)pLysS was transformed with the resulting
pETMCN-EAVNH H6-Rrp4-Rrp41 Rrp42 vector for co-
expression of the N-terminal hexahistidine-tagged Rrp4
and untagged Rrp41 and Rrp42 SsoExosome components.
Co-expression was induced at an OD600 of 0.6 with 1
mM IPTG and induced cells were grown at 37◦C for 3 h.
SsoExosome was purified as described previously (21,22).
The sequences of all expression plasmids were verified by
DNA sequencing prior to transformation into the E. coli
BL21(DE3)pLysS expression strain. Following expression
and purification, the identity of the recombinant proteins
was confirmed by LC-MS of tryptic digests (performed at
the Astbury Centre, University of Leeds, UK).
Exoribonuclease assays
Assays were carried out in reaction mixtures containing
700 nM 5′-fluorescein amidite (FAM)-A20 RNA substrate
(Dharmacon), 240 nM enzyme (EcPNPase, SspPNPase
(Sigma), hPNPase or SsoExosome), 15 mM Tris pH 8,
112.5 mM NaCl, 3.75 mMMgCl2 and 0.045 mMNa2PO4.
Reactions were performed in the absence and presence
of 3.75 mM sodium citrate. This concentration of citrate
was chosen to be equimolar to the Mg2+ concentration
and at approximately the Kd for the E. coli enzyme (47).
Assays were incubated at 37◦C for 10 min for EcPNPase
and SsoExosome, 30 min for SspPNPase and 60 min for
hPNPase, to allow for their different relative activities under
the assay conditions used. Reactions were terminated by
the addition of 0.1 M ethylenediaminetetraacetic acid and
reaction products resolved by denaturing 7.5 M urea 20%
polyacrylamide gel electrophoresis. Gels were visualised
using a Fujifilm FLA-5000 phosphorimager and quantified
by densitometry using ImageJ (Rasband WS, ImageJ, U.S.
National Institutes of Health, Bethesda, Maryland, USA,
http://imagej.nih.gov/ij/, 1997–2016).
RESULTS
In silico molecular docking of citrate into PNPase and the
archaeal exosome
The first hint that citrate might regulate PNPase came from
structural studies of the PNPase PH-hexamer core from E.
coli (9). In these, 0.2 M ammonium hydrogen citrate had
been present in the crystallisation buffer, and the resulting
structure contained eight bound citrate molecules (9). Two
citrate molecules were located at the active site in all three
monomers (9,47). One citrate molecule (Cit 1) occluded the
catalytic centre, interacting with S437, S438 and S439 in
the PBR and H487, K494 and a Mg2+ ion, coordinated by
D486 and D492, in the MBR (Figure 1C and 2A; 9,47).
The second citrate molecule (Cit 2) mimicked the position
of the scissile phosphate in an RNA substrate, interacting
with R93 of RBRI and R399 and H403 of RBRII (Figures
1C and 2A; 9,47). Given these binding positions, it was
predicted that citrate would inhibit PNPase activity and,
critically, exoribonuclease activity was attenuated in the
presence of citrate (47). A further two citrate molecules
were present in only one of the monomers and were located
at the vestigial site (9,47), a site related to the active site
by structural duplication but having lost the capacity for
catalysis (47). At this site, the citrate molecules were bound
by arginines R153, R372, R405 and R409 and this binding
was also shown to modulate PNPase activity, most likely
through an allosteric mechanism (47).
When the crystal structure of the PNPase core together
with the KH domains from H. sapiens PNPase was
subsequently reported, it too had crystallised in a buffer
containing citrate. In this structure, only two molecules of
citrate were observed per PNPase monomer, both at the
active site (13). There was no evidence of citrate binding to
a vestigial site. Alignment of the EcPNPase and hPNPase
protein sequences shown in Figure 1C reveals that of the
10 residues identified to be involved in citrate-binding in
the EcPNPase active site, 9 are conserved in hPNPase.
Only EcPNPase H487 is not conserved; in this position,
hPNPase has a tyrosine. Analysis of the interactions
between hPNPase and citrate in the crystal structure was
performed using the program MOE and revealed that all
nine of the conserved residues in hPNPase are involved in
citrate-binding whereas the non-conserved tyrosine residue
does not interact with citrate (Figures 1C and 2B). This
indicates that, in terms of citrate-binding, variability at this
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Figure 2. Docking of citrate into the PNPase/archaeal exosome active site. The lowest-energy poses obtained for two citrate ions docked into (A) E. coli
PNPase, (B) H. sapiens PNPase, (C) S. antibioticus PNPase and (D) S. solfataricus Exosome. The protein backbone of the docked structure is shown as
ribbons. The catalytic Mg2+ ion is shown as a magenta sphere. Docked citrate ions are shown as yellow sticks and orange sticks for the Cit 1 and Cit 2 sites,
respectively. For E. coli PNPase andH. sapiens PNPase, the citrate molecules observed in the crystal structures are shown as light grey sticks and dark grey
sticks for the Cit 1 and Cit 2 sites, respectively. The docking score obtained for each of the docked citrate ions is indicated in the top right of each panel.
position is tolerated. Lin et al. (13) did not go on to test the
effect of citrate on hPNPase activity. However, based on the
sequence homology, it would be predicted that citrate would
inhibit hPNPase, similar to EcPNPase.
With mounting evidence that citrate binds to the active
site of two distantly-related PNPases, we decided to
investigate whether the citrate-binding site is conserved in
other PNPases and/or the homologous archaeal exosome.
Molecular docking is a valid computational approach
to test the potential for ligand binding in silico before
moving on to more resource-consuming experimental
methodologies (55,56).
An alignment of the active site sub-sites for the PNPases
and archaeal exosomes for which there is structural
information available, highlighting the residues involved
in citrate-binding in the EcPNPase and hPNPase crystal
structures, is shown in Figure 1C. Comparison of the
four bacterial PNPase sequences shows that 8 of the 10
citrate-binding residues, originally identified in EcPNPase,
are absolutely conserved. However, SanPNPase contains
two substitutions: one at the EcPNPase H487 position
that, as noted above, can tolerate variability and a second
is a conservative substitution of threonine for serine at
the position of EcPNPase S438 (Figure 1C). The residues
involved in citrate-binding in hPNPase, as discussed above,
are also highly conserved relative to EcPNPase. In contrast,
only 4 of the 10 residues involved in citrate-binding
in EcPNPase are absolutely conserved in the archaea
homologues making it more difficult to predict, based on
sequence alone, whether citrate is likely to bind to the
exosome (Figure 1C).
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These nine protein sequences were similarly analysed to
investigate the citrate-binding site observed at the vestigial
site of EcPNPase and the resulting alignment of the three
citrate-binding motifs is shown in Supplementary Figure
S1. The evidence for conservation of citrate-binding at this
site is much weaker than for the active site. None of the four
residues identified to bind citrate at the EcPNPase vestigial
site are absolutely conserved (Supplementary Figure S1)
and citrate was not bound at this location in the hPNPase
crystal structure (13). Taking both of these observations
into consideration, citrate-binding to the vestigial site was
not investigated further.
Based on these initial sequence comparisons, structures
for EcPNPase and SanPNPase were selected as bacterial
representatives formolecular docking studies. The structure
for hPNPase was selected as the only structure available for
a eukaryotic PNPase, and the SsoExosome structure was
selected as the most characterised of the archaeal exosomes.
In order to validate the in silico approach, we first decided
to re-dock citrate into the structures of EcPNPase and
hPNPase, since structural studies had already reported
that both of these proteins are capable of binding two
molecules of citrate at their active site (9,13,47). The
structures for EcPNPase and hPNPase were prepared,
including placement of the catalytic Mg2+ ion and energy
minimisation, in MOE. Root mean square deviations
calculated between the original crystal structures and
the structures prepared for docking are presented in
Supplementary Table S5 and indicate that this energy
minimisation process did not significantly alter either
protein structure. Putative ligand-binding sites were then
identified using MOE and defined by the placement of
dummy atoms. Encouragingly, potential ligand-binding
sites were identified at the active site of both EcPNPase and
hPNPase, the known citrate-binding sites. A citrate ion was
then docked into each of the structures and, as shown in
Figure 2A and B, it docked at the active site (yellow sticks)
at the position of Cit 1 in the crystal structures (light grey
sticks). The lowest-energy 30 unique poses were retained for
each docking calculation and they all placed the citrate ion
in this location, albeit in slightly different orientations. The
docking scores (S values) for all 30 poses are summarised in
the box plot in Figure 3. Due to limitations of the docking
software, only a single citrate ion could be docked into
each structure in each experiment. As two molecules of
citrate bound to the active site of EcPNPase and hPNPase
in the crystal structures, we also wanted to explore the
potential for a second citrate ion to bind. In order to
do this, we used the lowest-energy pose with one citrate
ion docked as the starting point for a second round of
docking. The second citrate ion docked (Figure 2A and B,
orange sticks) at the equivalent location of Cit 2 observed
in the crystal structures (Figure 2A and B, dark grey
sticks). However, as shown in Figure 3, the S values for this
second docked citrate ion were higher (less favourable) than
those obtained for Cit 1 for both EcPNPase and hPNPase.
Overall, these results are consistent with the conclusion
that the in silico molecular docking protocol successfully
identifies the citrate-binding sites in both EcPNPase and
hPNPase.
Figure 3. Docking scores for citrate docked into PNPase/the archaeal
exosome. A box plot of the molecular operating environment (MOE)
docking scores for two citrate ions docked into the active site of E. coli
PNPase, S. antibioticus PNPase, H. sapiens PNPase and S. solfataricus
Exosome. Individual data points are shown as grey circles with the
coloured boxes representing the interquartile range and the horizontal
line within the box indicating the median docking score. The Citrate 1
docking scores are for 30 unique poses obtained when a single citrate ion
was docked into the protein structure. The Citrate 2 docking scores are for
30 unique poses obtained when a second citrate ion was docked into the
lowest energy pose obtained with one citrate molecule already docked.
Having demonstrated the validity of our approach, we
next wanted to try docking citrate into the structure
of a PNPase that has not previously been shown to
bind citrate. We decided to start with the most divergent
PNPase for which structural information is available. E.
coli, C. crescentus and C. burnetii all belong to the phylum
proteobacteria and all 10 of the residues involved in citrate-
binding in EcPNPase are conserved in the PNPases from
the other two bacteria. In contrast, S. antibioticus belongs
to the phylum actinobacteria and, as discussed above, 8 of
the 10 residues involved in citrate-binding in EcPNPase are
conserved. The two differences are an alanine for histidine
substitution at the variability-tolerant EcPNPase H487
position and a conservative substitution of threonine for
serine at the equivalent position to EcPNPase S438 (Figure
1C). Thus, based on sequence, it would be predicted that
citrate would bind to SanPNPase. As shown in Figure 2C,
two citrate ions docked into the active site of SanPNPase.
S values obtained for the docking at the Cit 1 site were
comparable to those obtained for EcPNPase and hPNPase
(Figure 3). However, for the Cit 2 site, the docking scores
obtained were significantly higher than for either of the
other two PNPases (Figure 3).
The results obtained so far suggest that citrate-binding
could be a common property of PNPases. The next step was
to investigate the potential for citrate-binding to the more
distantly related archaeal exosome homologues. Similarly,
to the three PNPases, two citrate ions docked into the active
site of the SsoExosome (Figure 2D). The docking scores for
the Cit 1 site were similar to those obtained for all three
PNPases while the S values for the Cit 2 site were more
similar to those obtained for SanPNPase (Figure 3).
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Figure 4. Interactions observed between PNPase/the archaeal exosome and docked citrate. Heat maps summarising the protein ligand interaction
fingerprints (PLIFs) generated for the ten lowest-energy poses obtained when two citrate ions were docked into the active site of E. coli PNPase, S.
antibioticus PNPase, H. sapiens PNPase and S. solfataricus Exosome.
To analyse the docking results further and compare
the amino acids predicted to mediate citrate-binding in
the three PNPases and archaeal exosome, PLIFs were
generated for the ten lowest-energy poses with both one and
two citrate ions docked. PLIFs are effectively a barcode for
a particular protein:ligand complex, classifying interactions
according to whether the interaction is mediated through
the main chain or side chain, whether it is polar, non-
polar or a hydrogen bond and whether the interaction
is strong or weak (57). The frequency with which an
interaction was predicted between citrate and a particular
amino acid in the docking experiments was calculated
from the PLIFs and is summarised in the heat maps
presented in Figure 4. Based on the docking experiments,
similar interactions are predicted between citrate and the
four putative citrate-binding residues that are conserved
in EcPNPase, SanPNPase, hPNPase and SsoExosome
(EcPNPase positions R93 in RBRI, R399 in RBRII and
D486 and D492, via the Mg2+ ion in the MBR) in all four
complexes (Figure 4). The predicted interactions between
docked citrate and the two amino acids that are conserved
only in the three PNPase proteins (EcPNPase positions
H403 in RBRII and K494 in the MBR) are comparable for
the PNPases but there is no equivalent interaction predicted
between citrate and the amino acids that are substituted
at these positions in SsoExosome (L and P, respectively;
Figure 4). Neither sequence nor the predicted interaction
is conserved at the position of EcPNPase H487 in the
MBR (Figure 4). At the EcPNPase PBR, interactions are
frequently predicted between citrate and S437 and S438
with interactions between citrate and S439 predicted less
often. The amino acid sequence and pattern of predicted
interactions at the PBR is conserved in hPNPase (Figure
4). However, the substitution of threonine for serine at
the equivalent position to EcPNPase S438 in SanPNPase
appears to have altered the predicted interactions between
citrate and the positions equivalent to EcPNPase S438 and
EcPNPase S439. In the SsoExosome, EcPNPase positions
S437, S438 and S439 have been substituted for G, S and R,
respectively (Figure 1C). Despite this sequence variation,
significant interactions are predicted between citrate and
these three positions in the SsoExosome (Figure 4).
Inhibition of PNPase and Exosome exoribonuclease activity
by citrate
The in silico studies suggest that citrate-binding at the
enzyme’s active site is evolutionarily conserved in bacterial
and eukaryotic PNPases and the archaeal exosome.
For EcPNPase, this binding has been shown to inhibit
exoribonuclease activity providing a mechanism for the
fine-tuning of EcPNPase activity (47). We next wanted to
experimentally determine whether citrate is also capable of
inhibiting other PNPases and/or the archaeal exosome.
EcPNPase, hPNPase and the SsoExosome were
expressed in E. coli and purified to homogeneity and
recombinant Synechocystis sp. PNPase (SspPNPase)
was obtained from Sigma. SspPNPase was used in
place of SanPNPase as both have the same threonine
to serine substitution at position 438 in the PBR region
(Supplementary Figure S2). Exoribonuclease assays
using a 5′-fluorescently labelled A20 oligoribonucleotide
substrate were carried out for each enzyme/complex in the
presence and absence of citrate and analysed by denaturing
polyacrylamide gel electrophoresis. An end-point assay
performed under similar experimental conditions was
selected as the most direct way to compare all four
PNPase homologues. Representative gels for this assay
are shown in Figure 5. Comparison of the end-point
lanes for assays performed in the presence of citrate with
those performed in its absence show clear differences for
EcPNPase, SspPNPase, hPNPase and SsoExosome. In
general, in the presence of citrate, more of the full-length
oligoribonucleotide substrate remains at the end of the
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Figure 5. Inhibition of PNPase/the archaeal exosome exoribonuclease activity by citrate. Representative denaturing polyacrylamide gels for end-point
exoribonuclease assays carried out using 240 nM E. coli PNPase (10-min reaction duration), Synechocystis sp. PNPase (30 min), H. sapiens PNPase (60
min) or S. solfataricus Exosome (10 min) and 700 nM of a 5′-FAM-A20 RNA substrate. The absence or presence of 3.75 mM citrate during the assay is
indicated by a − or + sign above the lane, respectively. Lanes labelled S and E indicate samples taken at the start and end of the reaction, respectively.
assay and less of the substrate is fully converted to limit
products (Figure 5). There are also some differences in the
observed stalling positions in the presence of citrate (Figure
5). This is most striking for the SsoExosome. SsoExosome
stalls on oligoribonucleotides around 10 nucleotides in
length in the absence of citrate but completely stops at
this point in the presence of citrate (Figure 5). Stalling at
similar oligoribonucleotide lengths has been previously
reported for the A. fulgidus and P. abyssi exosomes when
these short oligoribonucleotides are no longer long enough
to bind to both the active site and the entrance to the
channel (25,26). Citrate-binding to the active site of the
SsoExosome could occlude the only RNA-binding site
possible for short oligoribonucleotides and may explain
our observation of more of the stalled product.
In an attempt to quantify the effect of citrate upon
exoribonuclease activity, the percentage of full-length RNA
substrate remaining at the end of the assay was determined
for each enzyme/complex in the absence and presence
of citrate (Table 1). Given that citrate appears to alter
stalling positions, we reasoned that this would provide the
fairest comparison across all three of the PNPases and the
SsoExosome. EcPNPase activity was clearly inhibited by
citrate, with∼2.5-fold more full-length substrate remaining
at the end of the assay in the presence of citrate than in
its absence (Figure 5; Table 1). This level of inhibition is
consistent with that observed previously for EcPNPase at
this citrate concentration (47) and suggests that attenuation
of exoribonuclease activity rather than complete inhibition
is likely to occur in vivo. Citrate also inhibited the
exoribonuclease activity of SspPNPase, hPNPase and
SsoExosome to a comparable degree as EcPNPase (Figure
5; Table 1). These results clearly demonstrate that citrate can
both bind to and inhibit these enzymes in vitro.
Sequence analysis of the citrate-binding site
The in silico and in vitro results so far suggest that citrate-
mediated inhibition of PNPase and exosome activity occurs
in all three domains of life. To assess how widely this
inhibitory mechanism is likely to be conserved we carried
out sequence analysis of 3509 prokaryotic PNPase, 252
eukaryotic PNPase and 69 Rrp41/Rrp42 exosome protein
sequences. The resulting sequence logos (50) for the four
active site sub-sites that we have demonstrated are involved
in citrate-binding are shown in Figure 6. Of the 10 residues
that were originally identified to be involved in citrate-
binding in EcPNPase, 8 are absolutely conserved in all
of the bacteria and eukaryotes examined (Figure 6). Only
positions corresponding to EcPNPase S438 in the PBR and
H487 in the MBR show variation. However, the docking
and activity results for EcPNPase, SanPNPase/SppPNPase
and hPNPase indicate that the sequence variation at these
positions is not critical for citrate-binding or citrate-
mediated inhibition. The sequence logos for the exosomes
(Figure 6) show that four of the residues involved in citrate-
binding in EcPNPase are absolutely conserved (R93 in
RBRI, R399 in RBRII and D486 and D492 in the MBR).
As for the PNPases, variation was observed at the non-
critical EcPNPase H487 position in the MBR and also in
the EcPNPase H403 position in RBRII and the EcPNPase
K494 position in the MBR. Most strikingly, the S(S/T)S
motif in the PBR of PNPases appears to have been replaced
by a G(T/S)R motif in the archaeal exosomes. However,
we have shown for the SsoExosome that citrate has the
potential to bind to this motif and, despite the overall
sequence divergence, the SsoExosome is inhibited by citrate
in vitro. Taken altogether these results suggest that all of the
PNPases and archaeal exosomes examined are likely to bind
to and be inhibited by citrate.
DISCUSSION
Small molecule metabolites, as trans-acting factors, are in a
unique position to directly link the cellular metabolic status
of a cell and RNase activity. There is a growing body of
evidence that such a feedback mechanism is employed in
bacteria. Firstly, associations between metabolic enzymes
and RNases have now been identified in multi-protein
complexes in a number of organisms. Twenty years ago
the glycolytic enzyme enolase was shown to be a canonical
component of the E. coli degradosome (58,59), and
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Table 1. Inhibition of PNPase/archaeal exosome exoribonuclease activity by citrate
Enzyme Percentage substrate remaining at assay end-point
− citrate + citrate
E. coli PNPase 2.2 ± 0.4 5.6 ± 1.5
Synechocystis sp. PNPase 2.2 ± 0.2 6.9 ± 2.2
H. sapiens PNPase 8.4 ± 2.8 22.8 ± 4.8
S. solfataricus Exosome 4.0 ± 0.5 13.6 ± 0.5
Values are the mean from at least three experimental repeats and the errors reported are the standard deviation.
Figure 6. Sequence conservation of the citrate-binding site in prokaryotes, eukaryotes and archaea. Sequence logos for the four motifs (labelled below the
sequence logos) comprising the active site/citrate-binding site in prokaryotic and eukaryotic PNPases and the archaeal exosome. Acidic residues are red and
basic residues are blue. Residues that are absolutely conserved are indicated by dashed boxes. Residues initially identified to be involved in citrate-binding
in E. coli PNPase are indicated by orange triangles above the sequence logos together with the residue numbering for E. coli PNPase.
recently it has been demonstrated that the C. crescentus
degradosome contains the Krebs cycle enzyme aconitase
(60). Degradosome-like complexes also appear to be
present in Bacillus subtilis (61,62) and Staphylococcus
aureus (63) and contain two glycolytic enzymes (enolase and
phosphofructokinase), four RNases (RNase Y, RNase J1,
RNase J2 and PNPase) and a helicase (CshA). There are
also indications that small molecule metabolites modulate
RNase activity. Gmr, a c-di-GMP phosphodiesterase,
affects the expression of RNase II in E. coli (64) implying
that the RNase levels are actually regulated by c-di-GMP.
Furthermore, PNPase activity has been shown to be directly
affected by ATP (45), c-di-GMP (46) and citrate (47) in E.
coli and (p)ppGpp in Streptomyces (65) and Nonomuraea
sp. (66). The present study indicates that citrate-mediated
inhibition of RNases may be far more widespread than
these earlier examples would suggest.
We had previously reported that citrate binds to and
inhibits the activity of E. coli PNPase (47). The level
of inhibition observed at physiological concentrations
of citrate suggested that attenuation of exoribonuclease
activity, rather than complete inhibition, is likely to occur
in vivo (47). We now demonstrate, both in silico and
in vitro, that PNPases from other bacterial species (S.
antibioticus and Synechocystis sp.) may also be susceptible
to inhibition by citrate, which suggests that this attenuation
is commonplace amongst prokaryotes. Furthermore, we
also show that the activity of both eukaryotic PNPase from
human mitochondria and the archaeal exosome complex
from S. solfataricus is similarly inhibited by citrate. Finally,
bioinformatics data suggest that the citrate binding site is
highly conserved; indicating that this mechanism of RNase
inhibition may be universally employed across all three
domains of life.
The molecular mechanism of citrate-mediated inhibition
of PNPase appears to involve two citrate molecules binding
to the active site, occluding the catalytic centre and the
neighbouring RNA-binding regions (47). In the EcPNPase
and hPNPase crystal structures, the citrate at the catalytic
centre (Cit 1) is bound by three serines at the PBR that are
required to bind the inorganic phosphate nucleophile (9),
and a lysine and Mg2+ ion, coordinated by two catalytic
aspartate residues, at the MBR. The binding of the second
citrate (Cit 2) is mediated by two arginines and a histidine
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that play a role in RNA-binding (Figures 1C, 2A and B).
Molecular docking studies similarly predicted that these
residues would be involved in citrate-binding in EcPNPase,
SanPNPase and hPNPase (Figures 2 and 4). Sequence
analysis revealed that for bacterial PNPases and those
from eukaryotic organelles, these amino acids are highly
conserved (Figures 1C and 6), as might be expected for
residues that are also known to be critical for enzyme
activity. Therefore, given the involvement of these particular
residues in citrate-binding, it is predicted that citrate-
mediated inhibition of PNPase activity is widely conserved.
Despite there being two possible citrate-binding sites
within the PNPase active site, we noted that in the first
round of docking the citrate ionwas always placed at the Cit
1 site, suggesting that this site has a higher affinity for citrate
than the Cit 2 site. The docking scores obtained for each
of the two citrate ions support this assertion (Figure 3). It
remains to be determined whether both citrates are required
for inhibition. Interestingly, the docking scores for Cit 2
for SanPNPase, which has a substitution of threonine for
serine at the equivalent position to EcPNPase S438 (Figure
1C), are much higher than for EcPNPase or hPNPase
(Figure 3). Nevertheless, SspPNPase, which also contains
the threonine for serine substitution, is still inhibited by
citrate (Figure 5).
Sequence conservation of both the active site and,
consequently, the putative citrate-binding residues is much
weaker in the more distantly related archaeal exosomes
(Figures 1C and 6). In particular, the PBR S(S/T)S motif,
that is required for phosphate-binding in PNPase (9), has
been replaced by anG(T/S)Rmotif in the exosomes (Figure
6). Despite the sequence variation, this motif has also been
shown to bind phosphate (25,26) and we have similarly
demonstrated the potential functional equivalence with
regard to citrate-binding for the S. solfataricus exosome
(Figures 2D and 4). As for SanPNPase, the docking
scores for Cit 2 for SsoExosome are significantly higher
than for EcPNPase and hPNPase (Figure 3). Again, this
suggests that sequence variation may affect citrate-binding,
although, as for SspPNPase, there is no apparent effect on
inhibition (Figure 5).
It remains to be determined whether the citrate-mediated
inhibition/attenuation of exoribonuclease activity that we
have clearly demonstrated in vitro, is utilised as a regulatory
strategy in vivo. For a metabolite such as citrate to
act as a regulator the intracellular concentration of the
metabolite/citrate must vary under different physiological
conditions and the response elicited must be dose-
dependent in this concentration range. For EcPNPase,
there is evidence to support citrate-mediated regulation.
Intracellular citrate concentrations in E. coli depend upon
the carbon source and have been reported to be 2 mM
for growth on glucose or glycerol and 20 mM for growth
on acetate (67). Furthermore, the level of inhibition of
EcPNPase by citrate observed in vitro correlates with citrate
concentration in this range (47). For other organisms, the
situation is less clear. There is a lack of metabolomics
data reporting intracellular citrate concentration(s) and
this information is non-trivial to obtain. Nevertheless,
taken together, our results strongly suggest that citrate-
mediated inhibition of RNase activity may be a common
phenomenon witnessed across all three domains of life.
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